Kjellin M., Wesslén T., Löfblad E., Lennerstrand J. and Lannergård A. 2018. The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort. Upsala Journal of Medical Sciences. 123, 1 (Mar. 2018), 50–56. DOI:https://doi.org/10.1080/03009734.2018.1441928.